193 related articles for article (PubMed ID: 23454896)
1. Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance.
Kraus M; Bader J; Overkleeft H; Driessen C
Blood Cancer J; 2013 Mar; 3(3):e103. PubMed ID: 23454896
[TBL] [Abstract][Full Text] [Related]
2. Ritonavir, nelfinavir, saquinavir and lopinavir induce proteotoxic stress in acute myeloid leukemia cells and sensitize them for proteasome inhibitor treatment at low micromolar drug concentrations.
Kraus M; Müller-Ide H; Rückrich T; Bader J; Overkleeft H; Driessen C
Leuk Res; 2014 Mar; 38(3):383-92. PubMed ID: 24418752
[TBL] [Abstract][Full Text] [Related]
3. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
[TBL] [Abstract][Full Text] [Related]
4. The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
Kraus J; Kraus M; Liu N; Besse L; Bader J; Geurink PP; de Bruin G; Kisselev AF; Overkleeft H; Driessen C
Cancer Chemother Pharmacol; 2015 Aug; 76(2):383-96. PubMed ID: 26099967
[TBL] [Abstract][Full Text] [Related]
5. Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir.
Abt D; Besse A; Sedlarikova L; Kraus M; Bader J; Silzle T; Vodinska M; Slaby O; Schmid HP; Engeler DS; Driessen C; Besse L
BJU Int; 2018 Apr; 121(4):600-609. PubMed ID: 29161753
[TBL] [Abstract][Full Text] [Related]
6. Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma.
Besse A; Stolze SC; Rasche L; Weinhold N; Morgan GJ; Kraus M; Bader J; Overkleeft HS; Besse L; Driessen C
Leukemia; 2018 Feb; 32(2):391-401. PubMed ID: 28676669
[TBL] [Abstract][Full Text] [Related]
7. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
[TBL] [Abstract][Full Text] [Related]
8. The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma.
Besse L; Kraus M; Besse A; Driessen C; Tarantino I
Sci Rep; 2023 Mar; 13(1):4411. PubMed ID: 36932175
[TBL] [Abstract][Full Text] [Related]
9. Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08).
Driessen C; Kraus M; Joerger M; Rosing H; Bader J; Hitz F; Berset C; Xyrafas A; Hawle H; Berthod G; Overkleeft HS; Sessa C; Huitema A; Pabst T; von Moos R; Hess D; Mey UJ
Haematologica; 2016 Mar; 101(3):346-55. PubMed ID: 26659919
[TBL] [Abstract][Full Text] [Related]
10. Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo.
Pierce MR; Robinson RM; Ibarra-Rivera TR; Pirrung MC; Dolloff NG; Bachmann AS
Leuk Res; 2020 Jan; 88():106271. PubMed ID: 31778912
[TBL] [Abstract][Full Text] [Related]
11. The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo.
Bono C; Karlin L; Harel S; Mouly E; Labaume S; Galicier L; Apcher S; Sauvageon H; Fermand JP; Bories JC; Arnulf B
Haematologica; 2012 Jul; 97(7):1101-9. PubMed ID: 22271897
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib- and carfilzomib-resistant myeloma cells show increased activity of all three arms of the unfolded protein response.
Kubicki T; Bednarek K; Kostrzewska-Poczekaj M; Luczak M; Lewandowski K; Gil L; Jarmuz-Szymczak M; Dytfeld D
Am J Cancer Res; 2022; 12(7):3280-3293. PubMed ID: 35968359
[TBL] [Abstract][Full Text] [Related]
13. Nelfinavir Inhibits the TCF11/Nrf1-Mediated Proteasome Recovery Pathway in Multiple Myeloma.
Fassmannová D; Sedlák F; Sedláček J; Špička I; Grantz Šašková K
Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32344880
[TBL] [Abstract][Full Text] [Related]
14. Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors.
Besse A; Besse L; Kraus M; Mendez-Lopez M; Bader J; Xin BT; de Bruin G; Maurits E; Overkleeft HS; Driessen C
Cell Chem Biol; 2019 Mar; 26(3):340-351.e3. PubMed ID: 30612952
[TBL] [Abstract][Full Text] [Related]
15. Hydroxychloroquine potentiates carfilzomib toxicity towards myeloma cells.
Baranowska K; Misund K; Starheim KK; Holien T; Johansson I; Darvekar S; Buene G; Waage A; Bjørkøy G; Sundan A
Oncotarget; 2016 Oct; 7(43):70845-70856. PubMed ID: 27683126
[TBL] [Abstract][Full Text] [Related]
16. Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo.
Escalante AM; McGrath RT; Karolak MR; Dorr RT; Lynch RM; Landowski TH
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1567-76. PubMed ID: 23572175
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib targets the caspase-like proteasome activity in cervical cancer cells, triggering apoptosis that can be enhanced by nelfinavir.
Bruning A; Vogel M; Mylonas I; Friese K; Burges A
Curr Cancer Drug Targets; 2011 Sep; 11(7):799-809. PubMed ID: 21762082
[TBL] [Abstract][Full Text] [Related]
18. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.
Kuhn DJ; Chen Q; Voorhees PM; Strader JS; Shenk KD; Sun CM; Demo SD; Bennett MK; van Leeuwen FW; Chanan-Khan AA; Orlowski RZ
Blood; 2007 Nov; 110(9):3281-90. PubMed ID: 17591945
[TBL] [Abstract][Full Text] [Related]
19. Insulin-Degrading Enzyme Is a Non Proteasomal Target of Carfilzomib and Affects the 20S Proteasome Inhibition by the Drug.
Tundo GR; Sbardella D; Oddone F; Grasso G; Marini S; Atzori MG; Santoro AM; Milardi D; Bellia F; Macari G; Graziani G; Polticelli F; Cascio P; Parravano M; Coletta M
Biomolecules; 2022 Feb; 12(2):. PubMed ID: 35204815
[TBL] [Abstract][Full Text] [Related]
20. High-dose carfilzomib achieves superior anti-tumor activity over low-dose and recaptures response in relapsed/refractory multiple myeloma resistant to lowdose carfilzomib by co-inhibiting the β2 and β1 subunits of the proteasome complex.
Zhou X; Besse A; Peter J; Steinhardt MJ; Vogt C; Nerreter S; Teufel E; Stanojkovska E; Xiao X; Hornburger H; Haertle L; Lopez MM; Munawar U; Riedel A; Han S; Maurits E; Overkleeft HS; Florea B; Einsele H; Kortüm KM; Driessen C; Besse L; Rasche L
Haematologica; 2023 Jun; 108(6):1628-1639. PubMed ID: 36727403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]